Loading...
XNAS
ARAY
Market cap28mUSD
Oct 08, Last price  
0.24USD
1D
-4.74%
1Q
0.04%
Jan 2017
-94.75%
IPO
-99.17%
Name

Accuray Inc

Chart & performance

D1W1MN
XNAS:ARAY chart
P/E
—
P/S
0.07
EPS
—
Div yield, %
—
Shrs. gr., 5y
5.91%
Rev. gr., 5y
0.28%
Revenues
402m
-12.34%
210,381,000233,598,000233,598,000221,625,000222,284,000409,223,000315,974,000369,419,000379,801,000398,800,000383,414,000404,897,000418,785,000382,928,000396,289,000429,909,000447,605,000446,551,000458,505,000401,947,000
Net income
-49m
L+2,992.02%
5,383,000609,000609,0002,841,000-26,682,000-72,042,000-103,219,000-35,448,000-40,209,000-25,504,000-29,579,000-23,899,000-16,430,0003,827,000-6,311,000-5,347,000-9,280,000-15,545,000-1,591,000-49,194,000
CFO
-7m
L
11,597,000-17,989,000-8,046,000-5,073,00012,403,000-38,279,000-66,177,000346,000-16,733,00033,538,000-380,00018,331,000-29,641,000-1,469,00038,512,000-2,400,00015,539,000-11,904,0002,860,000-6,981,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Accuray Incorporated, established in 1990 with its headquarters in Sunnyvale, California, specializes in the development, production, and distribution of sophisticated radiosurgery and radiation therapy systems. These advanced medical devices are designed to combat tumors and are deployed across a vast international market, spanning the Americas, Europe, the Middle East, India, Africa, Japan, China, and the wider Asia Pacific region. Among its key product lines is the CyberKnife System, an advanced robotic platform utilized for stereotactic radiosurgery and stereotactic body radiation therapy. This system is adept at treating a diverse range of malignant growths and tumors found throughout the body, including those affecting the prostate, lungs, brain, spine, liver, pancreas, and kidneys. Additionally, Accuray offers the TomoTherapy System, which incorporates the Radixact System – an integrated radiation therapy solution engineered to address a broad spectrum of cancer types. Beyond its core equipment, the company provides comprehensive support services to its clientele. These include ongoing post-purchase maintenance, system installation, operational training, and various other specialized professional services. Accuray employs a multi-pronged sales approach; within the United States, it primarily sells directly to healthcare institutions such as hospitals and independent treatment centers via its own sales force, augmented by sales agents and group purchasing organizations. Internationally, sales are conducted directly to clients, alongside a network of distributors and sales agents.

Key people

President, Chief Executive Officer, Director · since 2025
Suzanne Winter
President, Chief Executive Officer · since 2024
Leonel Peralta
Chief Operations Officer, Senior Vice President · since 2025
Sandeep Chalke
Senior Vice President, Chief Commercial Officer · since 2024
Jesse Chew
Senior Vice President, Chief Legal Officer and Corporate Secretary · since 2023
Ali Pervaiz
Chief Financial Officer, Senior Vice President · since 2022
Michael Murphy
Principal Accounting Officer, Vice President, Corporate Controller · since 2024
Independent Director · since 2019
Independent Director · since 2018
Anne Le Grand
Independent Director · since 2020
Steven Mayer
Independent Director · since 2025
Mika Nishimura
Independent Director · since 2021
Independent Director · since 2018
IPO date
Feb 08, 2007
Employees
1,044
Domiciled in
US
Incorporated in
US
Legal address
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
1240 DEMING WAY
MADISON, WI 53717
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT